MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 70 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,269,963 | -29.6% | 2,145,337 | -5.0% | 7.70% | -30.5% |
| Q2 2023 | $24,516,678 | +35.6% | 2,257,521 | -13.8% | 11.08% | +48.8% |
| Q1 2023 | $18,078,662 | -15.8% | 2,620,096 | -38.0% | 7.44% | +143.5% |
| Q4 2022 | $21,480,000 | +13.3% | 4,222,648 | +14.6% | 3.06% | -26.8% |
| Q3 2022 | $18,959,000 | 0.0% | 3,684,622 | 0.0% | 4.18% | +93.6% |
| Q2 2022 | $18,959,000 | -44.1% | 3,684,622 | +1.5% | 2.16% | -72.6% |
| Q1 2022 | $33,936,000 | -21.3% | 3,629,622 | 0.0% | 7.88% | -31.9% |
| Q4 2021 | $43,119,000 | +4.4% | 3,629,622 | 0.0% | 11.56% | +49.3% |
| Q3 2021 | $41,305,000 | -36.6% | 3,629,622 | -0.1% | 7.74% | -31.2% |
| Q2 2021 | $65,152,000 | +16.3% | 3,631,694 | +0.4% | 11.26% | +10.5% |
| Q1 2021 | $56,011,000 | +26.9% | 3,618,334 | 0.0% | 10.19% | +19.9% |
| Q4 2020 | $44,143,000 | +26.4% | 3,618,334 | +33.1% | 8.50% | +11.0% |
| Q3 2020 | $34,930,000 | – | 2,718,334 | – | 7.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |